The BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2020.

BIO Investor Forum features include:

- **Public and venture-stage** company presentations.
- **Expert-led workshops** on the latest market and investment opportunities with emphasis on drug and technology development.
- **BIO One-on-One Partnering™** meetings.
- **Premier opportunity to network** with industry executives and investors focused exclusively on life sciences.

**Audience Demographics**

**TARGET AUDIENCE**

Private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences.

**Companies by Primary Therapeutic Area**

- Neurological disease: 7%
- Infectious disease: 5%
- Inflammatory disease: 7%
- Cardiovascular disease: 6%
- Gastrointestinal disease: 6%
- Immune disorder: 6%
- Dermatological disease: 6%
- Endocrine disease: 5%
- Degeneration: 5%
- Hematological disease: 6%
- Metabolic disorder: 4%
- Respiratory disease: 3%
- Ocular disease: 3%
- Genitourinary disease: 3%
- Psychiatric disorder: 2%
- Genetic disorder: 2%
- Neoplasms: 14%
- All Others: 7%

**Investors by Investor Type**

- 62% Venture Capital (VC)
- 9% Other Family Offices
- 7% Individual Investors
- 7% Royalty/Debt Financing
- 5% Venture Philanthropy
- 4% Endowment/Foundation
- 4% Hedge/Mutual Fund (PM, Buy-Side Research)
- 3% Angel Investing
- 3% Corporate VC
- 3% Endowment/Foundation
- 2% Sell-Side Research
- 2% Other
- 1% Sell-Side Investment Bank
- 1% Sell-Side Research
- 1% Endowment/Foundation
- 1% Venture Philanthropy
- 1% Other
Audience Demographics, continued

1. **Companies by Number of Employees**
   - 77% < 50 Employees
   - 13% 51 - 1,000 Employees
   - 10% 1,000+ Employees

2. **Companies by Ownership**
   - 75% Private
   - 18% Public
   - 7% Other

3. **Companies by Region**
   - 82% USA
   - 7% Asia
   - 5% Other
   - 4% Europe

4. **Attendees by Job Title**
   - 44% Investor
   - 34% Executive
   - 25% Director
   - 7% Other
   - 5% Investor Forum Staff

5. **Companies by Type**
   - 42% Biopharma
   - 33% Investor
   - 25% Other

#BIF19 has investors representing 11 countries

#BIF19 has a record share of private company investors

Like being at JPM without the crowds.

#BIF19 • bio.org/investorforum
BIO One-on-One Partnering

BIO’s One-on-One Partnering™ system is the interactive platform that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide.

- **Pre-schedule** 30-minute private 1x1 meetings
- **Source** potential collaborations and funding opportunities with an international audience
- **Communicate** directly with prospective investors and C-level executives in biotech and pharma
- **Search** company and investor profiles for potential business partnerships

**Partnering activity is up MORE THAN 60%**

**Accepted meetings are up BY OVER 130%**

**More than 50 COMPANIES** are new in the partnering system
Why Companies Attend

- Meet one-on-one with new and current investors, analysts, and partnering companies.
- Get the pulse on the latest life sciences investment trends from sophisticated investment and company executives.
- Showcase your company story in presentations to qualified investors.
- Network with peers, investors and potential partners.

Why Investors Attend

- Hear from and meet with executives at the top life sciences growth companies.
- Evaluate fresh investment opportunities including compatible, complementary and competitive companies.
- Benefit from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.
- Get a ‘big picture’ overview of the industry and the issues affecting product innovation, capitalization, and commercialization.

2018 BIO Investor Forum

TOP THERAPEUTIC AREAS FOR SCHEDULED MEETINGS

“The investors were great. I don’t know what similar access I’ll have to such a collection again.”

“Excellent forum for meeting investors or alliance partners for biotech deals.”

#BIF19 • bio.org/investorforum
2019 Advisory Committee

Mahima Agochiya, PhD  
Business Development & Program Manager  
SPARK Translational Research Program, Stanford University

Janice Bourque  
Managing Director, Life Sciences  
Hercules Technology Growth Capital

Jason Camm  
Managing Director and Chief Medical Officer  
Thiel Capital LLO

Alice Chen, PhD  
Vice President  
Accelerator Life Science Partners

Jung Choi  
Chief Business & Strategy Officer  
Global Blood Therapeutics

Shelley Chu, MD, PhD  
Partner  
Abingworth

Rajeev Dadoo, PhD  
Partner  
S.R. One Limited

Gini Deshpande, PhD  
Founder & Chief Executive Officer  
NuMedii

Jack Florio  
Partner, Strategy Consulting Practice  
Deallus

Julie Gilmore, PhD  
Chief Operating Officer, Lilly Research Labs  
Eli Lilly and Company

Tao Huang, PhD, JD  
Venture Partner  
Cenova Capital

Charlotte Hubbert, PhD  
Partner  
Gates Foundation Venture Capital

Alexis Ji, PhD  
Partner  
Illumina Ventures

Margaret Kim  
Executive Director, Life Sciences  
JPMorgan Chase & Co.

Ravi Kiron, PhD  
Head, BioPharma External Innovation  
EMD Serono

Jennifer Landress  
Senior Vice President and Chief Operating Officer  
Biocom

Bill Martin, PhD  
President and Chief Operating Officer  
Blackthorn Therapeutics

Samantha Miller, MSc, MBA  
Co-Founder and Chief Operating Officer, Cadence Health; Chief Business Officer  
InCarda Therapeutics

Carolyn Ng, PhD  
Managing Director  
Vertex Ventures HC

Peter Noymer, PhD  
Former President and CEO  
Kedalion Therapeutics; Independent Advisor
2019 Advisory Committee, CONTINUED

Stephen Ritoch
Chairman & Chief Executive Officer
Blaise Group International

John Ryan
Managing Director
Wells Fargo Strategic Capital

Andrew Setikas
Senior Vice President, Business Development and Strategy
California Life Sciences Association

Mahendra G. Shah, PhD
Managing Director
Vivo Capital

Ruchita Sinha
Senior Director of Investments
Sanofi Ventures

Komathi Stem
Founder & Chief Executive Officer
monARC Bionetworks

Samuel Wu, MD, PhD
Managing Director
Acuris Partners

Asish Xavier, PhD
Vice President, Venture Investments
Johnson & Johnson Innovation – JJDC, Inc.
**BIO SPARK Showcase**

The BIO SPARK Showcase aims to provide an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding.

The BIO Investor Forum is historically well attended by the venture arms and business development units of major pharmaceutical companies, smaller specialty pharma/biotech companies looking to add to their pipelines, start-ups, and many early stage venture capital firms, making it the ideal setting for early stage assets from the university setting. Academics interested in partnering will present their programs and also have one-on-one discussions with interested parties.


---

**Presentation Schedule**

**Monday, October 21, 2019 • 12:45pm - 6:30pm**

<table>
<thead>
<tr>
<th>Time</th>
<th>SPARK Affiliate and Program</th>
</tr>
</thead>
</table>
| 12:45 PM - 12:50 PM | Welcome from SPARK Translational Research Program, Stanford Medicine  
Kevin Grimes, MD, Co-Director |
| 12:50 PM - 1:10 PM    | SPARK at Stanford – Bacchus Therapeutics  
**Novel Treatment for Kidney Cancer**  
Arvin Gouw |
| 1:10 PM - 1:30 PM    | SPARK Colorado  
**A Breakthrough Therapy for Triple-Negative Breast Cancer**  
TBD |
| 1:30 PM - 1:50 PM    | SPARK Taiwan  
**Selective Top2 Chemotherapeutics**  
TBD |
| 1:50 PM - 2:10 PM    | SPARK Norway  
**Novel Therapy for Ischemic Reperfusion**  
TBD |
| 2:10 PM - 2:30 PM    | SPARK Japan  
**Revolutionizing the Way We Treat Heart Failure**  
TBD |
| 2:30 PM - 2:40 PM    | Break |
| 2:40 PM - 3:00 PM    | SPARK Japan  
**Gene Engineering Tools for Optical Control of Crispr/Cas9-Cpf1, Cre-Loxp System**  
TBD |
| 3:00 PM - 3:20 PM    | SPARK Norway  
**A Novel Vaccine Platform Against Influenza**  
Gunnveig Grødeland |
### Presentation Schedule, CONTINUED

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:20 PM - 3:40 PM</td>
<td>Stanford University</td>
<td>Small Molecule for the Treatment of Type 1 Diabetes</td>
<td>Andy Wardle</td>
</tr>
<tr>
<td>3:40 PM - 4:00 PM</td>
<td>SPARK Germany</td>
<td>Recombinant Human Neuregulin1 (Rhnr1) for the Treatment Of Schwann Cell-Derived Nerve Sheath Tumors</td>
<td>Helen Morrison</td>
</tr>
<tr>
<td>4:00 PM - 4:10 PM</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:10 PM - 4:30 PM</td>
<td>SPARK Stanford – Rejuvenation Technologies</td>
<td>Transient Telomere Extension to Treat Liver Failure in Dyskeratosis Congenita Patients</td>
<td>John Ramunas</td>
</tr>
<tr>
<td>4:30 PM - 4:50 PM</td>
<td>SPARK Finland</td>
<td>Novel treatment modality for Limbal Epithelial Stem Cell Deficiency</td>
<td>Anni Mörö</td>
</tr>
<tr>
<td>4:50 PM - 5:10 PM</td>
<td>SPARK Norway</td>
<td>Repositioning of Existing Drugs to Prevent Ventricular Arrhythmias</td>
<td>TBD</td>
</tr>
<tr>
<td>5:10 PM - 5:30 PM</td>
<td>SPARK at Stanford</td>
<td>Charge-Altering Releasable Transporters (CARTS): New Materials enable a New Platform Technology for Gene Delivery, Vaccinations, and Cancer Immunotherapy</td>
<td>Tim Blake</td>
</tr>
<tr>
<td>5:30 PM - 5:50 PM</td>
<td>SPARK Colorado</td>
<td>Targeting AMPK in Glioblastoma</td>
<td>TBD</td>
</tr>
<tr>
<td>5:30 PM - 6:30 PM</td>
<td>SPARK Reception</td>
<td></td>
<td>Victors</td>
</tr>
</tbody>
</table>
Tuesday Schedule of Events

Schedule subject to change and speakers continue to be updated.


<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 AM - 5:30 PM</td>
<td>Partnering Customer Service Desk</td>
<td>Sussex Room</td>
</tr>
<tr>
<td>7:00 AM - 7:55 AM</td>
<td>Networking Breakfast</td>
<td>California West Room</td>
</tr>
<tr>
<td>7:20 AM - 5:30 PM</td>
<td>Satellite Partnering Desk</td>
<td>3rd &amp; 4th Floor</td>
</tr>
<tr>
<td>7:30 AM - 5:30 PM</td>
<td>Partnering Meetings</td>
<td>3rd &amp; 4th Floor</td>
</tr>
<tr>
<td>7:30 AM - 5:30 PM</td>
<td>Partnering Hospitality Suite</td>
<td>Room 334</td>
</tr>
<tr>
<td>9:00 AM - 4:15 PM</td>
<td>Company Presentations</td>
<td>Elizabethan Rooms A-D &amp; Yorkshire Room</td>
</tr>
</tbody>
</table>

Session at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM – 9:40 AM</td>
<td>The Next Wave of Cancer Treatments: Allogeneic Cell Therapies and Other Pioneers</td>
</tr>
<tr>
<td>9:45 AM – 10:40 AM</td>
<td>Private Investors’ Incubators for University-Sourced Ideas</td>
</tr>
<tr>
<td>10:45 AM – 11:40 AM</td>
<td>Gene Therapies: Pipelines Into A New Era for Patients</td>
</tr>
<tr>
<td>12:30 PM – 1:25 PM</td>
<td>Plenary: Policy Outlook on Biotech Investment from China</td>
</tr>
<tr>
<td>2:00 PM – 2:55 PM</td>
<td>Fireside Chat: Jean-Jacques Bienaimé, Chairman &amp; CEO, BioMarin</td>
</tr>
<tr>
<td>3:00 PM – 3:55 PM</td>
<td>Recruiting Talent to Meet Corporate Board Requirements and Representation Goals</td>
</tr>
<tr>
<td>4:00 PM – 4:55 PM</td>
<td>View from the Board: To IPO Now or Not?</td>
</tr>
</tbody>
</table>
The Next Wave of Cancer Treatments: Allogeneic Cell Therapies and Other Pioneers

Moderator: Amanda Murphy, Biotechnology Analyst, BTIG
Panelists: Rafael Amado, MD, EVP of Research & Development and Chief Medical Officer, Allogene
Benjamin R. Cowen, PhD, President & CEO, ImmunoMet
Jie D’Elia, PhD, Executive Director, Business Development Transactions, Bristol-Myers Squibb
Lalo Flores, PhD, Chief Executive Officer, Century Therapeutics
Gary Lee, PhD, Chief Scientific Officer, Senti Bio
Kanya Rajangam, MD, PhD, Senior Vice President and Chief Medical Officer, Nkarta Therapeutics

As the industry continues to do revolutionary research on cancer, a host of new treatment options for therapies are showing promising data to disrupt the spread of tumors and inching us closer to a world where cancers can be cured. This panel reviews emerging treatment options in cancer, including the next wave of CAR-T, NK cell, and other pioneering approaches, highlighting promises enabled by each and the challenges to be resolved on the path to approvals and helping patients worldwide.

Private Investors’ Incubators for University-Sourced Ideas

Moderator: Catherine Vorwald, Director of Life Sciences, The Labs @ Sterling Bay
Panelists: Mark S. Blumenkranz, MD, Managing Director, Lagunita Biosciences
Jennifer Cochran, PhD, Executive Chairman, xCella Biosciences
Chris Garabedian, Chairman and CEO, Xontogeny; Portfolio Manager—Venture, Perceptive Advisors
Julie Gilmore, PhD, Chief Operating Officer, Lilly Research Labs, Eli Lilly and Company
Kevin Grimes, MD, Co-Director, SPARK Translational Research Program, Stanford University
Satish Jindal, PhD, Managing Director, BioMotiv

Recognizing a persistent “valley of death” in funding for medical research past the government-grant stage, several organizations have recently launched specialized investment vehicles. These vehicles are specifically designed to support translational research for university-sourced ideas to become independent companies capable of moving biological ideas into human drug development and to attract conventional venture investors. Hear from investors, academics, and entrepreneurs pursuing these new approaches that resolve critical bottlenecks as they work to lower initial project risks and accelerate progress through proof-of-concept.
Gene Therapies: The Pipeline Towards a New Era for Patients

Moderator: Shyam Patel, PhD, Associate Director, Portfolio Development & Review, California Institute for Regenerative Medicine (CIRM)

Panelists: Kathie Bishop, PhD, Chief Scientific Officer, Locana
Jason Fontenot, PhD, Senior Vice President of Cell Therapy, Sangamo Therapeutics
Alexandra Forbes, PhD, President and Chief Executive Officer, MeiraGTx
Michelle Gilson, Principal, Cannacord Genuity Inc.
Gary Lee, PhD, Chief Scientific Officer, Senti Bio
Michael Narachi, MBA, President and CEO, CODA Biotherapeutics

Gene therapies have the potential to increase the healthspan of patients and offer new approaches to treating diseases, with sizable pipelines in development and the first commercialized therapies revealing preliminary lessons about value and access. Early leaders in the field have focused on rare diseases which continues to open the pathway for other treatments in more widespread diseases. Attend this session to hear from several developers working to change patients’ genetics and lives to become their own hopeful cures.

Policy Outlook on Biotech Investment from China

Moderator: Cameron Arterton, Vice President, Tax Policy, Biotechnology Innovation Organization

Joshua Gruenspecht, Of Counsel, Wilson Sonsini Goodrich & Rosati
James Huang, Managing Partner, Kleiner Perkins Caufield & Byers China

According to Pitchbook, Chinese venture capital investment in U.S. biotechs has declined more than 60% in the first half of 2019. The increased review of the Committee on Foreign Investment in the US (CFIUS) on transactions, national security concerns, and trade negotiations have created a new landscape for cross-border business. The session will explore how biotech companies can continue to raise capital, the proposed rulemaking from CFIUS in the coming months, and a pathway for companies to remain innovative while CEOs and investors navigate these changes.
Tuesday, October 22, 2019  •  2:00 PM - 2:55 PM

FIRESIDE CHAT

California East Room

Fireside Chat with Jean-Jacques Bienaimé, Chairman and CEO, BioMarin

Moderator: Simone Fishburn, PhD, Vice President and Editor in Chief, BioCentury Inc.

Tuesday, October 22, 2019  •  2:00 PM - 3:00 PM

AFTERNOON NETWORKING REFRESHMENTS

California West Room

Tuesday, October 22, 2019  •  3:00 PM - 3:55 PM

BUSINESS PANEL

California East Room

Recruiting Talent to Meet Corporate Board Requirements and Representation Goals

Moderator: Cissy S. Young, PhD, Managing Director, Russell Reynolds Associates
Panelists: Matthew Fust, Independent Advisor to Life Sciences Companies
KT Moortgat, PhD, Director, AbbVie Ventures
William J. Newell, Chief Executive Officer, Sutro Biopharma
Amanda K. Packel, JD, Managing Director, Rock Center for Corporate Governance at Stanford University

By the end of 2019, publicly traded companies in California must have at least one woman director and those targets will increase by 2021. Massachusetts, Pennsylvania, and New Jersey along with other states have considered similar targets which will impact the biotechnology industry. As start-ups and small and medium sized biotech companies consider company growth and future exits, starting early with inclusive hiring practices and board recruitment has become a business priority. Attend this session to gain insight on corporate governance best practices and tips on conducting searches for companies to remain innovative and competitive in this changing environment. Resources for leadership teams and boards will be shared including tools created as part of BIO’s recently launched “Right Mix Matters” campaign.
BUSINESS PANEL

View from the Board: To IPO Now or Not?

Moderator: Michael O’Donnell, Partner, Morrison & Foerster LLP

Invited Panelists: Linda Grais, MD, Former CEO, Ocera Therapeutics
Chris Lowe, Chief Financial Officer, Cortexyme
Saira Ramasastry, Managing Partner, Life Sciences Advisory

With uncertain market conditions and concerns about realistic valuation expectations, innovative biotechs are trying to pinpoint the right time to go public. The right executive team and a clear, strategic roadmap have become more imperative as companies continually receive mixed signals from potential bookrunners and concerns are raised over IP in course of making a compelling case for going public and gaining access to capital markets. This panel will review how to structure those conversations and decisions around the current landscape and be as productive as possible toward timing the market accurately for a future IPO.

WELCOME RECEPTION

Tuesday, October 22, 2019 • 5:30 PM - 6:30 PM

Mission Bay, 32nd Floor
Wednesday Schedule of Events

Schedule subject to change and speakers continue to be updated.


### Wednesday, October 23, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 AM - 5:30 PM</td>
<td>Partnering Customer Service Desk</td>
<td>Sussex Room</td>
</tr>
<tr>
<td>6:50 AM - 5:00 PM</td>
<td>Satellite Partnering Desk</td>
<td>3rd &amp; 4th Floor</td>
</tr>
<tr>
<td>7:00 AM - 7:55 AM</td>
<td>Networking Breakfast</td>
<td>California West Room</td>
</tr>
<tr>
<td>7:00 AM - 5:00 PM</td>
<td>Partnering Meetings</td>
<td>3rd &amp; 4th Floor</td>
</tr>
<tr>
<td>7:00 AM - 4:30 PM</td>
<td>Partnering Hospitality Suite</td>
<td>Room 334</td>
</tr>
<tr>
<td>9:00 AM - 3:45 PM</td>
<td>Company Presentations</td>
<td>Elizabethan Rooms A-D &amp; Yorkshire Room</td>
</tr>
</tbody>
</table>

### Sessions at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM – 9:40 AM</td>
<td>Progress in CNS Drug Development Outside Dementia</td>
</tr>
<tr>
<td>9:45 AM - 10:40 AM</td>
<td>Advice on Pitching to Family Offices, Venture Philanthropies and Other Non-Private Equity Funding Sources</td>
</tr>
<tr>
<td>10:45 AM - 11:40 AM</td>
<td>Molecular Diagnostics: Drivers of New Investor Interest and Reimbursement Success</td>
</tr>
<tr>
<td>12:00 PM – 1:25 PM</td>
<td>Fireside Chat: Wende Hutton, General Partner, Canaan</td>
</tr>
<tr>
<td>1:45 PM – 2:40 PM</td>
<td>Separating Artificial Intelligence Hype from the Real Utility in Drug Development</td>
</tr>
<tr>
<td>2:45 PM – 3:55 PM</td>
<td>Best Practices in Biopharma Alliances with Digital Therapeutics Partners</td>
</tr>
<tr>
<td>4:00 PM – 4:55 PM</td>
<td>Market Outlook – Taking the Temperature of the IPO Market in an Era of Large Pharma M&amp;A</td>
</tr>
</tbody>
</table>
Progress in CNS Drug Development Outside Dementia

Panelists: Alice Chen, PhD, Vice President, Accelerator Life Science Partners
Tao Huang, PhD, JD, Venture Partner, Cenova Capital
Ellen Lubman, Chief Business Officer, Impel NeuroPharma
Robert Molinari, PhD, Founder and CEO; Director, Retrotepe

Recent studies from the National MS Society have estimated that nearly one million people in the United States are suffering from Multiple Sclerosis. Millions more suffer from schizophrenia, and thousands more from other CNS disorders that remain without a cure. In order to address the unmet medical needs of this patient population, dozens of companies from across the biotechnology industry are involved in late-phase clinical trials that are exploring the efficacy of different drug treatments on a variety of CNS disorders. On the investment side of the equation, neurology companies had the third highest number of biopharma deals in the first half of 2019, with over $800 million invested, according to the Silicon Valley Bank Mid-Year Report 2019. Hear from researchers and biotech executives involved in CNS drug development to gain insight into how the industry is expanding and the current clinical trials that have the potential to provide life-changing therapeutic solutions.

Advice on Pitching to Family Offices, Venture Philanthropies, and Other Non-Private Equity Funding Sources

Moderator: Maura Little, Executive Director, Cambia Grove
Panelists: Deanna Belsky, PhD, Associate, Dolby Family Ventures
Bob Crutchfield, Managing Director, BrightEdge Ventures
Reza Halse, PhD, Vice President and Head, BD&L Pacific Innovation Hub and President, MRL Ventures Fund, Merck & Co., Inc.
Charlotte Hubbert, PhD, Partner, Gates Foundation Venture Capital
Peter Lomedico, Senior Advisor, T1D Fund, JDRF
Christopher Penland, PhD, Vice President of BioPharma Programs, Cystic Fibrosis Foundation

With investment on the rise and the biotechnology industry continuously providing enormous reward opportunities, the demographic of investors has started to shift from the typical stakeholder. How should CEOs approach these potential partners and successfully secure a funding round? This session will feature experienced voices explaining the strategies to employ to properly satisfy a potential investor’s expectation and secure the desired capital.
**Molecular Diagnostics: Drives of New Investor Interest and Reimbursement Success**

**Moderator:** Benjamin Soule, MD, Global Search and Evaluation Lead—Business Development, Bristol-Myers Squibb

**Panelists:**
- Alexis Ji, PhD, Partner, Illumina Ventures
- Trevor Martin, Co-Founder and CEO, Mammoth Biosciences
- Richard J. Wenstrup, MD, Chief Medical Officer, Epic Sciences

As the biotechnology industry continues to address unmet medical needs across a wide variety of diseases and disorders, emerging innovative diagnostics methods are paving the way for earlier detection and increased levels of response to treatment. Companion and molecular diagnostics offer advanced methods of identifying biomarkers for cancer and other diseases and allow for the application of bespoke immune-based therapies. Additionally, Diagnostics Analytics deals spiked in the first half of 2019, with 119 deals totaling $2.164 billion, and are predicted to continue a three-year upward trend, according to the Silicon Valley Bank Mid-Year Report 2019. This panel explores the novel drug and product development from diagnostics companies in the industry that drive funding and reimbursement.
THERAPEUTIC SESSION

Separating Artificial Intelligence Hype from Real Utility in Drug Development

Panelists: Josep Bassaganya-Riera, DVM, PhD, Chairman and CEO, Landos Biopharma
Gini Deshpande, PhD, Founder & Chief Executive Officer, NuMedii
Bill Martin, PhD, President and Chief Operating Officer, Blackthorn Therapeutics
Krishnan Nandabalan, PhD, President and CEO, InveniAI

Recent data shows venture investment in AI-focused biopharma companies reached a new high of $1.4B through the first half of this year, according to CB Insights. However, the wide variance in applications and algorithms has complicated the ability to map progress in drug development techniques. As leaders in this space now begin to point to molecules moving into development and early clinical results, the prioritization of tools for other biotechs to consider adopting becomes clearer. This session will examine where AI can improve current drug discovery and development versus technological promises that are still years away from delivery.

AFTERNOON NETWORKING REFRESHMENTS

California West Room
Wednesday, October 23, 2019 • 2:45 PM - 3:55 PM

THERAPEUTIC PANEL

Best Practices in Biopharma Alliances with Digital Therapeutics Partners

Moderator: Megan Zweig, Head of Research, Rock Health
Invited: Panelists:
- David B. Klein, Chairman, President & CEO, Click Therapeutics
- Javier Garcia Palacios, PhD, Director Digital Health Ventures #G4A, Bayer
- Lucia Savage, Chief Privacy and Regulation Officer, Omada Health
- Ruchita Sinha, Senior Director of Investments, Sanofi Ventures

As the FDA has standardized the approval pathway for digital therapeutics, an increasing number of such therapies are reaching patients, often in collaboration with existing biopharma companies. Rock Health released an in-depth study earlier this year identifying four success factors that must be shared for such partnerships: value proposition of the project, organizational commitment, evidence standards, and channel strategy with business model. This session will feature Rock Health’s specific data then discuss the opportunities and challenges with digital therapeutics and biopharma alliance partners themselves.

Wednesday, October 23, 2019 • 4:00 PM - 4:55 PM

BUSINESS PANEL

Market Outlook – Taking the Temperature of the IPO Market in an Era of Large Pharma M&A

Moderator: Greg Wade, PhD, Managing Director, Healthcare Investment Banking, BTIG
Panelists:
- Shawn Cross, Managing Director, Healthcare Investment Banking, JMP Securities
- James Healy, MD, PhD, General Partner, Sofinnova
- Margaret Kim, Executive Director, Life Sciences, JPMorgan Chase & Co.
- John Kollins, President & Chief Executive Officer, Satsuma Pharmaceuticals
- Bibhash Mukhopadhyay, PhD, Principal, New Enterprise Associates
- Megan Zweig, Head of Research, Rock Health

As we start to close out 2019, the mixed signals regarding the appetite for IPOs are off from 2018’s strong finish. This year’s 33 offerings in the 1H have totaled $2.992 billion, compared to the $3.484 billion seen in the 36 offerings from last year. Large pharma M&A deals, however, continue to surprise and raise questions about a temporary market shift or a lasting trend. Are venture funding trends being affected by IPO success rates? With market volatility also on the rise aided by continued global trade tensions, the second half of 2019 raises concerns about the endurance of high valuations. This session will examine the path forward while highlighting the availability of quality targets for funding and the patterns of exits in the market.
2019 Participating Investors*

Below is a representative list of participating investment firms and sell side research analysts for the 2019 BIO Investor Forum.

3E Bioventures
AbbVie
ABES Venture Partners
Abingworth Management
Accelerator Life Science Partners
Acuris Partners
Adjuvant
Agent Capital
Agilent Technologies
Aleph Capital
Alexandria Venture Investments
Alignment Ventures
Altamont Pharmaceutical Holdings
Altitude Life Science Ventures
Andreesen Horowitz
Aquilo Capital
Arch Venture Partners
Arix Bioscience
ARTIS Ventures
Asahi Kasei America
Asajes Medical
Asajes Ventures
Asset Management Ventures
Astellas Innovation Management
Astellas Pharma US
Astellas Venture Management
ATEL Ventures
Atheneo Ventures
Band of Angels
Barbara Lavery
Beacon Capital
Biocozt Capital
Biodealitions
Biomark Capital
BioPacific Investors
Bios Partners
Biotech Alliances International
Bohe Angel Fund
Borex Capital
Boryung Holdings
BRONSO Capital Partners
Brace Pharma Capital
Brain Trust Accelerator Fund
BridgeBioPharma
BTIG
Canadian Imperial Bank of Commerce
Capital Family Office
Cato BioVentures
CEO Capital
Cenova Capital
Chaperone Investment
China Grand
Cl Investments
Cipla
Coventry Enterprises
Cowin Capital
Crosswave Management
CRV
CSC Leasing
Dabar Investment Associates
Dalton Investment
Danaher Life Sciences
Data Collective Venture Capital
DAYLI Partners
DCVC Bio
Delta Partners
DHVC
DigiTx Partners
Dolby Family Ventures
Dorset Capital
DoubleLine Capital
Dynamik Capital
East West Bank
Eisai
Emerson Collective
Esousa Holdings
FMG Ventures
F-Prime Capital Partners
Fujifilm Diosynth Biotechnologies
G4S Capital
GE Ventures
Genoa Ventures
Global Neurohealth Ventures
GreenSky Capital
Grey Sky Venture Partners
Hannol Ventures
Hbm Partners
HCM Healthcare Capital Management
HealthCare Royalty Partners
HEDA Ventures
Helicase Venture
Helix Ventures
Hemi Ventures
Hercules Capital
Hone Capital
Iaso Ventures
Illumina Accelerator
Illumina Ventures
In Capital
Inbio Ventures
INCI
Integral Group
Intuitive
IPF Partners
JHBio
Johnson & Johnson Development Corporation
Joyance Partners
Julu Co
Juvenile Diabetes Research Foundation (JDRF)
KB Financial Group
Kyoto University Innovation Capital
Laguna Ventures
Laurel Venture Capital
Life Science Angels
Lilly Asia Ventures
Lincoln Park Capital
Lumira Ventures
Lyfe Capital
Lymo Ventures
LYZZ Capital Advisors
Matthews Asia
Matthews International Capital Management
Maywell Capital
MDB Capital Group
Medical Ventures
Milestone Capital
Mitsui & Co. Global Investment
Momentum Biotech
MPPM Capital
MSQ Ventures
MyBioGate
Nan Fung Life Sciences
NanoDimension
NCL Technology Ventures
New Enterprise Associates (NEA)
Nomura Instinet
Northern Light Venture Capital
Novo Ventures (US)
OCV
Olive Tree Capital
Orends Capital
OSF Healthcare Ventures
Otsuka Pharmaceutical Co.
Oxford Finance
Palo Alto Investors
Panacea Venture Healthcare
Pappas Ventures
Perseverance Capital
Pharmanetstandard JSC
Pivotal BioVenture Partners
PoC Capital
Premier Partners
Presidio Partners
Preval Partners
Primer Capital
Qiming Venture Partners VSA
Quadrira Biosciences
Quan Capital
RBV Capital
Relentless Pursuit Partners
Remiges Ventures
Research Bridge Partners
Roche Venture Fund
Sanderling Ventures
Sandhill Angels
Sanofi
Santen Pharmaceutical Co.
Santen Ventures
Satter Medical Technology Partnership
Shanghai Henlius Biotech
Shenzhen Salubris Pharmaceuticals
Sincere Pharmaceutical Group
Sinar Mas Technology
Softinnova Ventures
SPRIM Ventures
SR One
StarLink Capital
StartUp Health
Steel Wolf Ventures
Taiho Ventures
Taiwania Capital
Takeda Ventures
Talfinium Investments
The Benchmark Company
The Leukemia & Lymphoma Society
Tosho USA
TransPacific Venture Capital Partners
Triple Ring Technologies
Ulreum Capital
VantagePoint Capital Partners
VenBio Partners
Vertex Venture Holdings
Vivo Capital
Voya Financial
W Global Capital
WARF Therapeutics
Washington Research Foundation Center
WBB Securities
Westlake Ventures
WI Harper Group
Xeraya Capital Life Venture
Y Combinator
Yonijin Capital
Yuhan USA
ZGC Capital
ZJ Future

*As of 10/07/2019
### 2019 Participating Companies*

<table>
<thead>
<tr>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bird Rock Bio</td>
</tr>
<tr>
<td>BlackThorn Therapeutics</td>
</tr>
<tr>
<td>Bloom Science</td>
</tr>
<tr>
<td>Boundless Bio</td>
</tr>
<tr>
<td>Brava Diagnostics</td>
</tr>
<tr>
<td>Breakthrough Genomics</td>
</tr>
<tr>
<td>BridgeBio Pharma</td>
</tr>
<tr>
<td>BridGenie Biosciences</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Company</td>
</tr>
<tr>
<td>Business France</td>
</tr>
<tr>
<td>California Institute for Regenerative Medicine</td>
</tr>
<tr>
<td>Cambia Grove</td>
</tr>
<tr>
<td>Canaccord Genuity</td>
</tr>
<tr>
<td>Cantabio Pharmaceuticals</td>
</tr>
<tr>
<td>Cardiogas Technologies</td>
</tr>
<tr>
<td>Caribou Biosciences</td>
</tr>
<tr>
<td>Carmell Therapeutics</td>
</tr>
<tr>
<td>Catalyst Pharmaceuticals</td>
</tr>
<tr>
<td>Cell Care Therapeutics</td>
</tr>
<tr>
<td>Celularity</td>
</tr>
<tr>
<td>Century Therapeutics</td>
</tr>
<tr>
<td>Cerevance</td>
</tr>
<tr>
<td>CerSci Therapeutics</td>
</tr>
<tr>
<td>Cesca Therapeutics</td>
</tr>
<tr>
<td>Chubb</td>
</tr>
<tr>
<td>Circle Pharma</td>
</tr>
<tr>
<td>Circumvent</td>
</tr>
<tr>
<td>City of Hope</td>
</tr>
<tr>
<td>Click Therapeutics</td>
</tr>
<tr>
<td>Clinical Network Services (CNS)</td>
</tr>
<tr>
<td>CODA Biotherapeutics</td>
</tr>
<tr>
<td>CohBar</td>
</tr>
<tr>
<td>Common Pharma</td>
</tr>
<tr>
<td>Contraline</td>
</tr>
<tr>
<td>Correlia Biosystems</td>
</tr>
<tr>
<td>Cortexyme</td>
</tr>
<tr>
<td>Corvidia Therapeutics</td>
</tr>
<tr>
<td>Courier Therapeutics</td>
</tr>
<tr>
<td>Cue Biopharma</td>
</tr>
<tr>
<td>Cystic Fibrosis Foundation</td>
</tr>
<tr>
<td>CytoDyn</td>
</tr>
<tr>
<td>Cytonus Therapeutics</td>
</tr>
<tr>
<td>Cytovia Therapeutics</td>
</tr>
<tr>
<td>Da Volterra</td>
</tr>
<tr>
<td>Dalriada Therapeutics</td>
</tr>
<tr>
<td>Dalton Bioanalytics</td>
</tr>
<tr>
<td>Daré Bioscience</td>
</tr>
<tr>
<td>Dealus Consulting</td>
</tr>
<tr>
<td>DeBiopharm International</td>
</tr>
<tr>
<td>Deciduous Therapeutics</td>
</tr>
<tr>
<td>Decoy Biosystems</td>
</tr>
<tr>
<td>Deep Lens</td>
</tr>
<tr>
<td>DellNova</td>
</tr>
<tr>
<td>Delta-Fly Pharma</td>
</tr>
<tr>
<td>Demuris</td>
</tr>
<tr>
<td>Dia-beat-it</td>
</tr>
<tr>
<td>DNALite Therapeutics</td>
</tr>
<tr>
<td>DOTBIO</td>
</tr>
<tr>
<td>Drusolv Therapeutics</td>
</tr>
<tr>
<td>Dyadic International</td>
</tr>
<tr>
<td>Dyve Biosciences</td>
</tr>
<tr>
<td>EA Pharma</td>
</tr>
<tr>
<td>Economic Development Agency</td>
</tr>
<tr>
<td>Brandenburg</td>
</tr>
<tr>
<td>Edesa Biotech</td>
</tr>
<tr>
<td>Elevian</td>
</tr>
<tr>
<td>Elex Biotech</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>EngineBio</td>
</tr>
<tr>
<td>Engrail Therapeutics</td>
</tr>
<tr>
<td>Ensysce Biosciences</td>
</tr>
<tr>
<td>EnterTroy Bio</td>
</tr>
<tr>
<td>Epic Sciences</td>
</tr>
<tr>
<td>Epilepsy Foundation</td>
</tr>
<tr>
<td>Equillum</td>
</tr>
<tr>
<td>Espero BioPharma</td>
</tr>
<tr>
<td>ethris GmbH</td>
</tr>
<tr>
<td>Eureka Therapeutics</td>
</tr>
<tr>
<td>Evaluate</td>
</tr>
<tr>
<td>Exicure</td>
</tr>
<tr>
<td>Exxel Pharma</td>
</tr>
<tr>
<td>Facile Therapeutics</td>
</tr>
<tr>
<td>Fellow Health</td>
</tr>
<tr>
<td>Fenologica Biosciences</td>
</tr>
<tr>
<td>Fibrocell Science</td>
</tr>
<tr>
<td>First Light Diagnostics</td>
</tr>
<tr>
<td>Foresee Pharmaceuticals</td>
</tr>
<tr>
<td>Fortress Biotech</td>
</tr>
<tr>
<td>Galimedix Therapeutics</td>
</tr>
<tr>
<td>Gel4Med</td>
</tr>
<tr>
<td>GLeadator Biosciences</td>
</tr>
<tr>
<td>GlobalConnectWorks</td>
</tr>
<tr>
<td>GlobalData</td>
</tr>
<tr>
<td>GlyTech</td>
</tr>
<tr>
<td>Golden Biotechnology Corp.</td>
</tr>
<tr>
<td>Greenwich LifeSciences</td>
</tr>
<tr>
<td>H.C. Wainwright &amp; Company</td>
</tr>
<tr>
<td>Halloran Consulting Group</td>
</tr>
<tr>
<td>Halo Biosciences</td>
</tr>
<tr>
<td>Haystack Sciences</td>
</tr>
<tr>
<td>Heartseed</td>
</tr>
<tr>
<td>Helixmith Co.</td>
</tr>
<tr>
<td>Hercules Capital</td>
</tr>
<tr>
<td>Histogen</td>
</tr>
<tr>
<td>Honeylab</td>
</tr>
<tr>
<td>Hyloric Biotech</td>
</tr>
<tr>
<td>Hyggeia Biological Laboratories</td>
</tr>
<tr>
<td>IACTA Pharmaceuticals</td>
</tr>
<tr>
<td>Illumina Ventures</td>
</tr>
<tr>
<td>Ilya Pharma</td>
</tr>
<tr>
<td>Immuncet Therapeutics</td>
</tr>
<tr>
<td>Immunophotonics</td>
</tr>
<tr>
<td>Impact Therapeutics</td>
</tr>
<tr>
<td>Impel NeuroPharma</td>
</tr>
<tr>
<td>IMV</td>
</tr>
<tr>
<td>InCarda Therapeutics</td>
</tr>
<tr>
<td>Incysus Therapeutics</td>
</tr>
<tr>
<td>Informa</td>
</tr>
<tr>
<td>InMed Pharmaceuticals</td>
</tr>
<tr>
<td>Innoffly Management</td>
</tr>
<tr>
<td>Innovate Biopharmaceuticals</td>
</tr>
<tr>
<td>Intabio</td>
</tr>
<tr>
<td>Interface Biologics</td>
</tr>
<tr>
<td>InterVenn Biosciences</td>
</tr>
<tr>
<td>InveniAI</td>
</tr>
<tr>
<td>Inversago Pharma</td>
</tr>
<tr>
<td>Invivo Sciences</td>
</tr>
<tr>
<td>ISOTHrive</td>
</tr>
<tr>
<td>Jaan Biotherapeutics</td>
</tr>
<tr>
<td>JT Pharma</td>
</tr>
<tr>
<td>Kaléo Pharma</td>
</tr>
<tr>
<td>Kedalion Therapeutics</td>
</tr>
<tr>
<td>Kelun Pharmaceuticals</td>
</tr>
<tr>
<td>Kezar Life Sciences</td>
</tr>
<tr>
<td>Kineta</td>
</tr>
<tr>
<td>Kinoxis Therapeutics</td>
</tr>
<tr>
<td>Kissee America</td>
</tr>
<tr>
<td>Kleo Pharmaceuticals</td>
</tr>
<tr>
<td>KPI Therapeutics</td>
</tr>
<tr>
<td>Kyorin USA</td>
</tr>
<tr>
<td>L.E.K. Consulting</td>
</tr>
<tr>
<td>Landos Biopharma</td>
</tr>
<tr>
<td>LaVoieHealthScience</td>
</tr>
<tr>
<td>Leibniz Institute on Aging</td>
</tr>
<tr>
<td>Leidos</td>
</tr>
<tr>
<td>Lempo Therapeutics</td>
</tr>
<tr>
<td>Lexent Bio</td>
</tr>
<tr>
<td>LIPAC Oncology</td>
</tr>
<tr>
<td>Locana</td>
</tr>
<tr>
<td>Locust Walk</td>
</tr>
<tr>
<td>Lonza Pharma &amp; Biotech</td>
</tr>
<tr>
<td>LSA</td>
</tr>
<tr>
<td>Lung Therapeutics</td>
</tr>
<tr>
<td>Lunit</td>
</tr>
<tr>
<td>Lynx Biosciences</td>
</tr>
<tr>
<td>MacDougall Biomedical Communications</td>
</tr>
<tr>
<td>MAIA Biotechnology</td>
</tr>
<tr>
<td>Mammoth Biosciences</td>
</tr>
<tr>
<td>Mandalmed</td>
</tr>
<tr>
<td>Mantra Bio</td>
</tr>
<tr>
<td>MaxCyte</td>
</tr>
<tr>
<td>Medsavana</td>
</tr>
<tr>
<td>Membio</td>
</tr>
<tr>
<td>Merck KGaA</td>
</tr>
<tr>
<td>Metcela</td>
</tr>
<tr>
<td>MetVital</td>
</tr>
<tr>
<td>MicroRadical 380</td>
</tr>
<tr>
<td>Mitsubishi Tanabe Pharma</td>
</tr>
<tr>
<td>MMSC</td>
</tr>
<tr>
<td>Molecular Theranostics</td>
</tr>
<tr>
<td>Monash University</td>
</tr>
<tr>
<td>MorphoceII Technologies</td>
</tr>
<tr>
<td>Morrison &amp; Foerster</td>
</tr>
<tr>
<td>MUSC Foundation for Research Development</td>
</tr>
</tbody>
</table>

*A as of 07/07/2019*
2019 Participating Companies CONTINUED

Mycovia Pharmaceuticals  
Nammi Therapeutics  
Nanostics  
National Institutes of Health, NHLBI  
National Taiwan University College of Medicine  
Navidea BioPharmaceuticals  
Navigant Consulting  
Navigen Pharmaceuticals  
NB Health Laboratory  
NDA Group  
Nelum  
NeOnc Technologies  
Neumentum  
Neurobo Pharmaceuticals  
Neurocycle Therapeutics  
Neuroscience Trials Australia  
Neuroscientific Biopharmaceuticals  
New Orleans Business Alliance  
New5win  
Nikon Instruments  
Nkarta Therapeutics  
North Carolina Biotechnology Center  
Novelogics Biotechnology  
Novotech  
Nucleus Network  
NuvOx Pharma  
Okava Pharmaceuticals  
Omada Health  
Oncolytics Biotech  
Oncolyze Therapeutics  
Oncomatrix Biopharma  
OncoSenX  
Opiant Pharmaceuticals  
Opus Biotech Communications  
Oragenics  
Orion Biotechnology  
OrthoMed  
Orthopaedic Research and Education Foundation  
OrthoTrophix  
OxSonicx Therapeutics  
OxStem Limited  
Pacylex Pharmaceuticals  
PAION AG  
Panjab University  
Paras Biopharmaceuticals Finland Oy  
Phanes Therapeutics  
Phenomic AI  
Phosphatlin Therapeutics  
Privo Technologies  
Proteina  
Quadriga Biosciences  
Rafael Pharmaceuticals  
Rakuten Medical Japan K.K.  
Rejuvenation Technologies  
Resverlogix Corporation  
Retrotope  
Riptide Bioscience  
RubrYc Therapeutics  
SAB Biotherapeutics  
Sapience Therapeutics  
Satellos Bioscience  
Satsumo Pharmaceuticals  
SCIBAC  
Seelos Therapeutics  
SEnG Precision Medicine  
SENS Research Foundation  
Senti Biosciences  
Sentien Biotechnologies  
Serimmune  
SFDA Therapeutics  
ShareVault  
Shifa Biomedia Corporation  
Shinkai Therapeutics  
Siragen Pharmaceuticals  
Siu Pharma  
SmartPharma Therapeutics  
Sofinnova Ventures  
Spectrum Pharmaceuticals  
SpinalCyte, LLC  
Splash Pharmaceuticals  
Stanford SPARK Program  
Stanford University  
Sterling Bay  
Sterto Therapeutics  
Structure Based Design  
Summit Therapeutics  
Surrozen  
Symvivo Corporation  
SynDevRx  
Synthetic Biologics  
Synthex  
Tampere University  
TargetGene Biotechnologies  
Technology Venture Commercialization  
TEGA Therapeutics  
Teikoku Pharma USA  
Tempo Therapeutics  
Terran Biosciences  
Terumo BCT  
The Money Channel NYC  
The University of Chicago  
The University of Texas MD Anderson  
TheraTarget  
ThinkCyte  
Thrombo Therapeutics  
Tierra Biosciences  
Torrey  
Tosk  
Traffic Therapeutics  
Tranquis Therapeutics  
Trilogy Therapeutics  
Triurus Therapeutics  
TrovaGene  
True Bearing Diagnostics  
Tulane University School of Medicine  
US Pharmacopeial  
UC Davis-Office of Research  
Ultivue  
University of California, Davis  
University of California, San Francisco  
University of Colorado Anschutz Medical Campus  
University of Michigan  
University of Oslo  
University of Texas at Austin  
University of Texas, MD Anderson Cancer Center  
University of the Sunshine Coast Clinical Trials Centre  
University of Tsukuba  
University of Utah TVC  
Univfy  
Unnatural Products  
Valtor  
Valley Fever Solutions  
Valtari Bio  
VaporoX  
Varsona Pharmaceuticals  
VelosBio  
Venture Valuation  
Vida Strategic Partners  
vidaDA Therapeutics  
Vigeo Therapeutics  
Viramal  
Vistara Biosciences  
VitrVax  
VM Oncology  
Vona Oncology  
Vybion  
Wenbli Therapeutics  
Wheelhouse  
xCella Biosciences  
Xoc Pharmaceuticals  
Xontogeny  
X-Therma  
Yiviva  
Zenith Epigenetics  
Zenopharm
### Presenting Companies

#### CARDIOVASCULAR
- Bilix
- Brava Diagnostics, Inc.
- Elex Biotech, Inc.
- InvivoSciences Inc.
- Jaan Biotherapeutics LLC
- RCE Technologies, Inc.
- Resverlogix Corp. (TSX:RVX)
- Shifa Biomedical Corporation

#### CNS/NEUROLOGICAL
- 712 North
- Abreos Biosciences, Inc.
- Amygdala Neurosciences
- Attentive Therapeutics
- BioTrillion
- BioXcel Therapeutics (NASDAQ:BTAI)
- Cantabio Pharmaceuticals
- Ceravance, Inc.
- Circumventv
- EnterTroy Bio
- Epilepsy Foundation
- Exicure (NASDAQ:XCUR)
- MetVital, Inc.
- NeuroScientific Biopharmaceuticals Ltd (ASX:NSB)
- SHINKEI Therapeutics
- Terran Biosciences
- Vybion, Inc
- Xoc Pharmaceuticals, Inc.

#### DERMATOLOGY
- Accuitis, Inc.
- Dyve Biosciences

#### DIAGNOSTICS
- Breakthrough Genomics
- Interpace Diagnostics (NASDAQ:IDXG)
- Molecular Theranostics, LLC
- Nanostics Inc
- True Bearing Diagnostics, Inc

#### DIGITAL HEALTH
- Dalton Bioanalytics
- Deep Lens, Inc.
- Univfy

#### GASTROINTESTINAL
- Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT)
- ISOThrive LLC
- OrphoMed, Inc.

#### GENE/CELL THERAPY
- Alivita Biomedical
- American Gene Technologies
- Caribou Biosciences
- Cytonus Therapeutics Inc.
- Ilya Pharma
- Lempo Therapeutics
- MaxCyte, Inc. (LSE | AIM:MXCT)
- Senti Biosoences
- Sentien Biotechnologies, Inc.
- SmartPharm Therapeutics

#### IMMUNOLOGY
- BCell Solutions, Inc.
- Kineta, Inc.
- Landos Biopharma
- Leidos (NYSE:LDOS)
- Serimmune, Inc.
- Traffic Thera

#### INFECTIOUS DISEASES
- Adjuvance Technologies Inc.
- Avails Medical, Inc.
- First Light Diagnostics
- Mycovia Pharmaceuticals
- SciBac Inc.
- Summit Therapeutics (NASDAQ:SMMT)

#### INFLAMMATION
- Acquist Therapeutics, Inc.
- ActoBio Therapeutics, Inc.
- Aristeia Therapeutics
- Lupa Bio, Inc.
- SFA Therapeutics

#### MEDICAL DEVICES
- Aethlon Medical, Inc. (NASDAQ:AEMD)
- Azure8
- Vaporox
<table>
<thead>
<tr>
<th><strong>METABOLIC DISEASES</strong></th>
<th>SynDevRx, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bird Rock Bio, Inc.</td>
<td>SyntheX</td>
</tr>
<tr>
<td>CohBar (NASDAQ:CWBR)</td>
<td>TheraTarget</td>
</tr>
<tr>
<td><strong>MULTIPLE THERAPEUTICS</strong></td>
<td>Vigeo Therapeutics, Inc.</td>
</tr>
<tr>
<td>Altimmune Inc. (NASDAQ:ALT)</td>
<td>VM Oncology</td>
</tr>
<tr>
<td>Aptorum Group Limited (NASDAQ: APM)</td>
<td>xCella Biosciences</td>
</tr>
<tr>
<td>Synthetio Biologics, Inc. (NYSE:SYN)</td>
<td>Zenith Epigenetics</td>
</tr>
<tr>
<td><strong>ONCOLOGY</strong></td>
<td>Zenopharm, LLC</td>
</tr>
<tr>
<td>ACT Genomics</td>
<td></td>
</tr>
<tr>
<td>Actinium Pharmaceuticals, Inc. (NYSE:ATNM)</td>
<td></td>
</tr>
<tr>
<td>Aegle Therapeutics Corp.</td>
<td></td>
</tr>
<tr>
<td>AllMM Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Antev Ltd</td>
<td></td>
</tr>
<tr>
<td>BioMarker Strategies, LLC</td>
<td></td>
</tr>
<tr>
<td>Biphar LLC</td>
<td></td>
</tr>
<tr>
<td>Boundless Bio, Inc.</td>
<td></td>
</tr>
<tr>
<td>Cytovia Therapeutics</td>
<td></td>
</tr>
<tr>
<td>DotBio Pte, Ltd.</td>
<td></td>
</tr>
<tr>
<td>Foresee Pharmaceuticals Co., Ltd. (TPEx:8576)</td>
<td></td>
</tr>
<tr>
<td>GLAdiator Biosciences</td>
<td></td>
</tr>
<tr>
<td>Golden Biotechnology Corp. (OTC Taipei Exchange:4312)</td>
<td></td>
</tr>
<tr>
<td>Greenwich LifeSciences</td>
<td></td>
</tr>
<tr>
<td>ImmunoMet Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Impact Therapeutics</td>
<td></td>
</tr>
<tr>
<td>IMV Inc. (NASDAQ:IMV)</td>
<td></td>
</tr>
<tr>
<td>Incysus Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>InterVenn Biosciences</td>
<td></td>
</tr>
<tr>
<td>Kleo Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>MAIA Biotechnology, Inc.</td>
<td></td>
</tr>
<tr>
<td>Mantra Bio</td>
<td></td>
</tr>
<tr>
<td>Nammi Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>NaNotics, LLC</td>
<td></td>
</tr>
<tr>
<td>NeOnc Technologies Inc</td>
<td></td>
</tr>
<tr>
<td>Nurix Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>Oncolytics Biotech Inc. (NASDAQ:ONCY)</td>
<td></td>
</tr>
<tr>
<td>OncoSenX</td>
<td></td>
</tr>
<tr>
<td>Oragenics, Inc.</td>
<td></td>
</tr>
<tr>
<td>Orion Biotechnology Canada</td>
<td></td>
</tr>
<tr>
<td>OxSonics Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Pacylex Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td>Phanes Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>Phosplatin Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Rakuten Medical</td>
<td></td>
</tr>
<tr>
<td>Riptide Bioscience, Inc.</td>
<td></td>
</tr>
<tr>
<td>RubrYc Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>Sapience Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>Splash Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td><strong>OPHTHALMOLOGY</strong></td>
<td></td>
</tr>
<tr>
<td>AxeroVision, Inc.</td>
<td></td>
</tr>
<tr>
<td>Drusolv Therapeutics</td>
<td></td>
</tr>
<tr>
<td>IBI</td>
<td></td>
</tr>
<tr>
<td>Palatin Technologies (NYSE:PTN)</td>
<td></td>
</tr>
<tr>
<td><strong>ORPHAN/RARE DISEASES</strong></td>
<td></td>
</tr>
<tr>
<td>Arcturus Therapeutics (NASDAQ:ARCT)</td>
<td></td>
</tr>
<tr>
<td>InMed Pharmaceuticals Inc (TSX:IN)</td>
<td>Lung Therapeutics</td>
</tr>
<tr>
<td>TargetGene Biotechnologies</td>
<td></td>
</tr>
<tr>
<td><strong>OTHER</strong></td>
<td></td>
</tr>
<tr>
<td>MandalMed, Inc.</td>
<td></td>
</tr>
<tr>
<td>Savanamed</td>
<td></td>
</tr>
<tr>
<td>ThromboTherapeutics Inc.</td>
<td></td>
</tr>
<tr>
<td><strong>PAIN MANAGEMENT</strong></td>
<td></td>
</tr>
<tr>
<td>CerSci Therapeutics</td>
<td></td>
</tr>
<tr>
<td>Ensysce Biosciences, Inc.</td>
<td></td>
</tr>
<tr>
<td>Neumentum, Inc.</td>
<td></td>
</tr>
<tr>
<td>NeuroBo Pharmaceuticals (NASDAQ Capital Markets: NRBO)</td>
<td></td>
</tr>
<tr>
<td><strong>PLATFORM FOR THERAPEUTICS</strong></td>
<td></td>
</tr>
<tr>
<td>Abalone Bio, Inc.</td>
<td></td>
</tr>
<tr>
<td>Anima Biotech Inc.</td>
<td></td>
</tr>
<tr>
<td>Antidote</td>
<td></td>
</tr>
<tr>
<td>Engine Biosciences</td>
<td></td>
</tr>
<tr>
<td>Tierra Biosciences</td>
<td></td>
</tr>
<tr>
<td>VISTARA BIOSCIENCE LLC</td>
<td></td>
</tr>
<tr>
<td><strong>QUALIFIED CELLS &amp; TISSUES</strong></td>
<td></td>
</tr>
<tr>
<td>Membio</td>
<td></td>
</tr>
<tr>
<td><strong>REGENERTIVE MEDICINE</strong></td>
<td></td>
</tr>
<tr>
<td>Aspect Biosystems</td>
<td></td>
</tr>
<tr>
<td>Cesca Therapeutics Inc. (NASDAQ:KOOL)</td>
<td></td>
</tr>
<tr>
<td>Heartseed Inc.</td>
<td></td>
</tr>
<tr>
<td>Histogen Inc.</td>
<td></td>
</tr>
<tr>
<td>Orthopaedic Research and Education Foundation</td>
<td></td>
</tr>
<tr>
<td>Satellos Bioscience Inc.</td>
<td></td>
</tr>
<tr>
<td>REPRODUCTIVE/SEXUAL HEALTH</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Daré Bioscience (NASDAQ:DARE)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RESPIRATORY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethris GmbH</td>
</tr>
<tr>
<td>NB Health Laboratory Co., Ltd</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TOOLS/DRUG DEVELOPMENT SUPPORT TECH</th>
</tr>
</thead>
<tbody>
<tr>
<td>FenoLogica Biosciences, Inc.</td>
</tr>
<tr>
<td>Haystack Sciences</td>
</tr>
<tr>
<td>Intabio</td>
</tr>
</tbody>
</table>
Registration and Housing Information

BIO offers a number of ways to conference attendees to save money on their registration fees.

Discounted rates apply to the following:

- Biotech companies that have raised less than $25 million in capital.
- Presenting companies bringing three or more attendees.
- Companies bringing more than two employees.
- Corporations or other entities that use biotechnology or related technologies for research and development of products or information.
- Academic institutions.

Qualified institutional and venture investors are eligible for complimentary registration.

Westin St. Francis Hotel
335 Powell Street
San Francisco, CA 94102